MBS, now

MBS is now a part of BBI Solutions, and we are proud to be exhibiting at the MEDICA trade fair in Düsseldorf, Germany November 13-16, 2017. For the first time, our customers will have an opportunity to stop by HALL 3A STAND 3AB02-1 and learn how together we can be an end-to-end partner in immunoassay development. Services Antibody development Antibody production Lateral flow development with Morffi™ Signal Enhancement Technology Novarum™ image capture technology and smartphone reader Products Antigens Antibodies Biobank Enzymes Gold Reagents
Read More

Categories: News.

View a Sample Antigen Review

Leverage 27 years of immunology and antibody development experience by letting the hybridoma development team at MBS conduct a thorough review of antigen options to meet your project goals. The MBS Antigen Review service can help identify risks and guide the proposal of a successful immunization strategy.  The report generated will include a comparative analysis of: Sequence, Features and Structural Analysis of the Antibody Target Linear Epitope Prediction Homology Analysis Tertiary Structural Analysis of Possible Epitopes A Review of Reagents on the Market and Recommendations for Use Sample Antigen Review (select full screen in bottom right corner of flip book for
Read More

Categories: News.

BBI Group acquires Maine Biotechnology Services

The BBI Group, partner to the world’s leading diagnostic and healthcare organisations, has entered into a definitive agreement to acquire the Maine Biotechnology Services, Inc. (MBS) located in Portland, Maine (USA). The acquisition of MBS will expand BBI’s portfolio during a period of expansion and growth. The company provides a range of products to the diagnostic, healthcare, research food sectors globally. MBS will add antibody development to its capability and product range. Lyn Rees, CEO of the BBI Group, said: “The acquisition of MBS perfectly complements our current product portfolio and coincides with our commercial team expansion, giving us important
Read More

Categories: Industry News and News.

MBS Exhibiting at AAPS National Biotechnology Conference in San Diego, Booth #716

MBS will be attending the AAPS National Biotechnology Conference in San Diego, CA., May 1-3, 2017. Sales and technical teams will be available at booth #716 to answer questions on how MBS custom antibody strategies and services can help you with all your antibody development needs. Stop by and see us.                     Email us at sales@mainebiotechnology.com to set up a meeting today!  
Read More

Categories: New Products and News.

MBS Exhibiting at PEGS in Boston, Booth #100

MBS will be attending the Essential Protein Engineering Summit in Boston, MA., May 1-5, 2017. Sales and technical teams will be available at booth #100 to answer questions on how MBS custom antibody strategies and services can help you with all your antibody development needs. Stop by and see us.                   Email us at sales@mainebiotechnology.com to request a meeting at PEGS in Boston, May 1-5!  
Read More

Categories: News.

Anti-Drug Antibody Reagent Development

Current industry best practices and FDA guidelines urge therapeutic antibody developers to use affinity-purified polyclonal antibodies in anti-drug assays for immunogenicity studies as well as controls for ongoing drug monitoring. MBS delivers sensitive and specific positive ADA controls through: Dedicated project management of polyclonal antibody development Goal-driven immunization strategies Advanced, application-specific screening of serum samples Custom affinity purification Lifetime supply of antibody generated within 5 months                 Learn More about Polyclonal Antibody Development   Read the MBS Biology of Antibodies Blog on the Detection of Therapeutic Antibodies
Read More

Categories: News.

New Hybridoma Development Project Manager at MBS

Maine Biotechnology Services, Inc. is pleased to announce the addition of Dr. Jennifer Walker as the MBS Hybridoma Project Manager.  Dr. Walker brings additional depth to the scientific team that works with customers to develop rich project plans that shorten timelines and mitigate risks.  She will be responsible for management and execution of those project plans, as well as analyzing and communicating data to facilitate timely, goal-driven decision making throughout the hybridoma development process. Prior to joining MBS, Dr. Walker was a doctoral candidate and research associate at the University of Maine focusing on B cell development, protein biochemistry, and
Read More

Categories: News.

Chikungunya and Norovirus Antibodies at AACC

Antibodies of Chikungunya Virus New epitope information is available for two monoclonal antibodies to Chikungunya virus.  MAB243P and MAB244P, developed and produced at MBS, react with the E2 glycoprotein of Chikungunya. All 3 Chikungunya antibodies developed by MBS do not cross-react with other alphaviruses. Learn More   Antibodies to Norovirus MBS offers a comprehensive panel of antibodies specific to Norovirus. The 7 antibodies include 1 specific for GI, 5 specific for GII and 1 antibody that recognizes both genotypes. Learn More     Stop by Booth #648 at AACC to see our complete offering of cGMP antibodies
Read More

Categories: News.

MBS Exhibiting at Booth #648 AACC 2016

Maine Biotechnology Services is exhibiting at AACC in Philadelphia, PA August 1-4th 2016.  Stop by Booth #648 to find out how MBS’s deep expertise in antibody development services can shorten timelines and improve project outcomes. In addition to custom antibody services, MBS offers a catalog of antibody products; developed, produced, and supported in house for maximum quality and price flexibility.  Antibodies to Norovirus, Chikungunya Virus, RSV, Adenovirus, Rotavirus, and Campylobacter jejuni are among our most popular sellers.  All MBS antibodies are produced under cGMP conditions and are available in bulk quantities.  Learn more:       Antibody Development   Antibody Production
Read More

Categories: News.

Keeping Tabs on Polyhistidine Tags | GEN Magazine Articles | GEN

Attitudes toward Affinity Purification Range from a Desire to Move beyond Old Specificity/Yield Trade-Offs to a Willingness to Explore New Polyhistidine Technology Spin-Offs Angelo DePalma, Ph.D.   Affinity tagging, a popular method for capturing or immobilizing proteins, has several incarnations, none more popular than polyhistidine tagging. In polyhistidine tagging, 6 to 10 histidine residues are added recombinantly to either the protein’s C- or N-terminus.   Fewer or more histidines are also possible. After expression, the protein is captured by means of immobilized metal affinity chromatography (IMAC). Subsequently, the protein is eluted in high purity by swamping the column with imidazole,
Read More

Categories: News and Press Releases.